The evidence framework of traditional Chinese medicine injection (Aidi injection) in controlling malignant pleural effusion: A clustered systematic review and meta-analysis

医学 恶性胸腔积液 胸膜成形术 内科学 荟萃分析 胸腔积液 中医药 随机对照试验 肿瘤科 病理 替代医学
作者
Cheng-Qiong Wang,Jiao Xu,Hong Jiang,Xiao-Tian Zheng,Yan Zhang,Xiao-Rong Huang,Fei She,Teng-Yang Fan,Lin Zhan,Jihong Feng,Qihai Gong,Xue Xiao,Xiaofan Chen,Zheng Xiao
出处
期刊:Phytomedicine [Elsevier]
卷期号:115: 154847-154847 被引量:5
标识
DOI:10.1016/j.phymed.2023.154847
摘要

Aidi injection (Aidi), a traditional Chinese medicine injection, is often practiced to control malignant pleural effusion (MPE). We performed a registered systematic review and meta-analysis (PROSPERO: CRD42022337611) to clarify the clinical role of Aidi in MPE, reveal optimal combinations of Aidi and chemical agents, their indications, therapeutic route and usage, and demonstrate their clinical effectiveness and safety. All randomized controlled trials (RCTs) about Aidi in controlling MPE were collected from Chinese and English databases (up to October 2022). We clustered them into multiple homogenous regimens, evaluated the risk-of-bias at outcome level using a RoB 2, extracted and pooled the data using meta-analysis or descriptive analysis, and finally summarized their evidence quality. All 56 studies were clustered into intrapleural administration with Aidi alone or plus chemical agents, and intravenous administration with Aidi for MPE. Intrapleural administration with Aidi alone displayed similar clinical responses on Cisplatin (DDP) alone. Only administration with Aidi plus DDP significantly improved complete response and quality of life, and displayed a low pleurodesis failure, disease progression, hematotoxicity, gastrointestinal and hepatorenal toxicity. For patients with moderate to massive effusion, Karnofsky Performance Status score ≥ 50 or anticipated survival time ≥3 months, Aidi (50 ml to 80 ml each time, one time each week and three to eight times) plus DDP (20 to 30 mg, 40 to 50 mg, or 60 to 80 mg each time) significantly improved clinical responses. Most results had moderate to low quality. Current evidences indicate that Aidi, a pleurodesis agent, plays an interesting clinical role in controlling MPE. Aidi plus DDP perfusion is a most commonly used regimen, which shows a significant improvement in clinical responses. These findings also provide an indication and possible optimal usage for rational drug use.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lucas应助优美紫槐采纳,获得10
刚刚
刚刚
张白完成签到,获得积分10
1秒前
研友_ZzaKqn完成签到,获得积分0
1秒前
孙文霞发布了新的文献求助10
2秒前
2秒前
科目三应助尊敬泽洋采纳,获得10
2秒前
忧郁人龙发布了新的文献求助10
3秒前
xl发布了新的文献求助10
3秒前
3秒前
wuyyuan发布了新的文献求助10
4秒前
passion发布了新的文献求助10
5秒前
5秒前
EOL发布了新的文献求助10
6秒前
啊嘀哩嘀哩完成签到,获得积分10
6秒前
杜客完成签到,获得积分10
6秒前
6秒前
量子星尘发布了新的文献求助10
8秒前
俭朴完成签到,获得积分10
9秒前
10秒前
11秒前
和平港湾完成签到,获得积分10
11秒前
xl完成签到,获得积分10
11秒前
silk发布了新的文献求助10
11秒前
12秒前
13秒前
orixero应助passion采纳,获得10
13秒前
14秒前
俭朴发布了新的文献求助10
14秒前
柒安完成签到 ,获得积分10
14秒前
pluto应助XCDF1采纳,获得10
14秒前
15秒前
15秒前
Jaden完成签到,获得积分10
17秒前
17秒前
17秒前
17秒前
思源应助含糊的灵雁采纳,获得10
18秒前
buno应助科研通管家采纳,获得10
18秒前
MYFuture应助科研通管家采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
人脑智能与人工智能 1000
花の香りの秘密―遺伝子情報から機能性まで 800
King Tyrant 720
Silicon in Organic, Organometallic, and Polymer Chemistry 500
Principles of Plasma Discharges and Materials Processing, 3rd Edition 400
El poder y la palabra: prensa y poder político en las dictaduras : el régimen de Franco ante la prensa y el periodismo 400
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5605558
求助须知:如何正确求助?哪些是违规求助? 4690129
关于积分的说明 14862351
捐赠科研通 4701941
什么是DOI,文献DOI怎么找? 2542175
邀请新用户注册赠送积分活动 1507804
关于科研通互助平台的介绍 1472113